Modulating Oncogenic Transcriptional Dysregulation with Small Molecule Chimeric Degraders of Cyclin-Dependent Kinase 9
Provided herein are bifunctional compounds that bind cyclin-dependent kinase 9 (CDK9) and/or promote targeted ubiquitination for the degradation of CDK9, a protein whose dysregulation is implicated in certain cancers. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer, methods of promoting the degradation of CDK9 and/or IKZF1, and methods of promoting the selective degradation of CDK9 (e.g., over IKZF1) by a compound or composition described herein.
Researchers
-
chimeric degraders of cyclin-dependent kinase 9 and uses thereof
European Patent Convention | Published application -
chimeric degraders of cyclin-dependent kinase 9 and uses thereof
United States of America | Pending
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.